Exelixis, Inc. (EXEL) stock has seen a remarkable surge in recent months, fueled by the strong performance of its lead drug Cabometyx and promising pipeline progress. The company’s efforts to expand its oncology portfolio and return value to shareholders solidify its position as a compelling investment opportunity in the biotech sector.